Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Tiessen, Renger G.
Kennedy, Ciara A.
Keller, Bradley T.
van Vliet, Andre A.
Funding for this research was provided by:
This study was funded by Lumena Pharmaceuticals (part of the Shire group of companies) (Not applicable)